{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:43:50Z","timestamp":1747183430716,"version":"3.40.5"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This noninterventional, retrospective study was a real\u2010life assessment of dose adaptation for six OTTs (afatinib, everolimus, palbociclib, pazopanib, sorafenib and sunitinib), at baseline and during treatment, and the reasons for the changes, in \u226570\u2010year\u2010old patients treated between February 2016 and August 2019. Data were compared with univariate models fitted with all variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 986 patients treated with OTT, the group of \u226570\u2010year\u2010old patients (n\u2009=\u2009122) received afatinib (15.6%), everolimus (14.8%), palbociclib (50.8%), pazopanib (9.8%), sorafenib (5.8%) or sunitinib (3.2%). At baseline, the prescribed OTT dose was adapted (reduction) in 29% of \u226570\u2010year\u2010old patients (35\/122). These 35 patients were significantly older (mean age 80 <jats:italic>vs<\/jats:italic> 74\u2009years, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001), and more frequently had a performance status score \u22652 (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.01) than the other patients (<jats:italic>n<\/jats:italic>\u2009=\u200987). In the standard dose group, higher toxicity grades (<jats:italic>P<\/jats:italic>\u2009=\u2009.18) and subsequent dose reduction (41% of patients, 36\/87) tended to be more frequent compared with the baseline adapted dose group (26%, 9\/35, <jats:italic>P<\/jats:italic>\u2009=\u2009.1). At the study end, 53% of patients in the whole cohort (65\/122) were taking a lower dose than the recommended one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>At OTT initiation, dose was adapted in 29% of older adults with cancer, rarely after a formal oncogeriatric evaluation (6.5% of all patients). In the absence of recommendations, clinical studies are needed to evaluate the efficacy and safety of baseline OTT dose reduction in older adults with cancer.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15285","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T05:34:45Z","timestamp":1645162485000},"page":"3370-3377","source":"Crossref","is-referenced-by-count":0,"title":["Oral targeted therapy dose adaptation in older patients with cancer: A real\u2010life French cohort"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4706-3784","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Carbasse","sequence":"first","affiliation":[{"name":"Department of Pharmacy Institut du Cancer de Montpellier  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-5044","authenticated-orcid":false,"given":"Fanny","family":"Leenhardt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Institut du Cancer de Montpellier  Montpellier France"},{"name":"Pharmacokinetic Laboratory University of Montpellier  Montpellier France"},{"name":"INSERM U1194 IRCM  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-061X","authenticated-orcid":false,"given":"William","family":"Jacot","sequence":"additional","affiliation":[{"name":"INSERM U1194 IRCM  Montpellier France"},{"name":"Department of Medical Oncology Institut du Cancer de Montpellier  Montpellier France"},{"name":"University of Montpellier  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Perrier","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Institut du Cancer de Montpellier  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Pinguet","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Institut du Cancer de Montpellier  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Viala","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Institut du Cancer de Montpellier  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2509385"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277\u2010014\u20101649\u2010y"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.005"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2019.06.019"},{"issue":"353","key":"e_1_2_10_7_1","first-page":"487","article-title":"Adherence to Medication","volume":"11","author":"Lars O","year":"2005","journal-title":"N Engl J Med"},{"key":"e_1_2_10_8_1","unstructured":"Ageingn.d.https:\/\/www.who.int\/westernpacific\/health-topics\/ageing(accessed December 4 2020)."},{"key":"e_1_2_10_9_1","unstructured":"INCA \u2013 Les cancers en France. n.d.https:\/\/www.e-cancer.fr\/ressources\/cancers_en_france\/(accessed December 22 2020)."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.430"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.15441\/ceem.17.261"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu540"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1627\u20104830(07)89954\u20105"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912\u2010017\u20100630\u20105"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/aco.0000000000000814"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.2.4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010019\u201003783\u20109"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.08.008"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8687"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu210"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.08.002"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115060"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(08)61039\u20109"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.44.2806"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e127"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11550"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.09.020"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.028"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.014"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899\u2010019\u201000524\u2010w"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058\u2010020\u201001263\u20100"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010017\u20103362\u20101"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds145"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9730"},{"key":"e_1_2_10_38_1","unstructured":"Pfizer.POLARIS: Palbociclib in hormone receptor positive advanced breast cancer: A prospective multicenter non\u2010interventional study. clinicaltrials.gov;2019."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959\u20108049(20)30568\u20102"},{"volume-title":"Phase I clinical and pharmacokinetic study of pazopanib in a population of frail elderly patients according SIOG criteria","year":"2018","author":"Institut Claudius Regaud","key":"e_1_2_10_40_1"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.06.013"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5362"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0319"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010019\u201002704\u20102"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15285","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T14:21:17Z","timestamp":1692714077000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/bcp.15285"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15285","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}